InVivo Therapeutics Holdings Corp. (NVIV): Price and Financial Metrics

InVivo Therapeutics Holdings Corp. (NVIV): $0.32

0.17 (-34.28%)

POWR Rating

Component Grades








Add NVIV to Watchlist
Sign Up

Industry: Biotech




#330 of 379

in industry

NVIV Price/Volume Stats

Current price $0.32 52-week high $2.40
Prev. close $0.49 52-week low $0.22
Day low $0.30 Volume 1,885,600
Day high $0.41 Avg. volume 8,249,015
50-day MA $0.69 Dividend yield N/A
200-day MA $1.05 Market Cap 995.77K

NVIV Stock Price Chart Interactive Chart >

InVivo Therapeutics Holdings Corp. (NVIV) Company Bio

InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 and is based in Cambridge, Massachusetts.

NVIV Latest News Stream

Event/Time News Detail
Loading, please wait...

NVIV Latest Social Stream

Loading social stream, please wait...

View Full NVIV Social Stream

Latest NVIV News From Around the Web

Below are the latest news stories about INVIVO THERAPEUTICS HOLDINGS CORP that investors may wish to consider to help them evaluate NVIV as an investment opportunity.

Why InVivo Therapeutics Shares Are Plunging Today

InVivo Therapeutics Holdings Corp (NASDAQ: NVIV) announced topline results from its INSPIRE 2.0 study of Neuro-Spinal Scaffold, a bioresorbable scaffold-based device for acute spinal cord injuries (SCI). The study did not meet its primary endpoint, which was assessed by the proportion of treated patients achieving an improvement of at least one American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade at six months post-scaffold implantation versus a control group that received stan

Yahoo | March 9, 2023

InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury

CAMBRIDGE, Mass., March 09, 2023--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI. The study did not

Yahoo | March 9, 2023

Read More 'NVIV' Stories Here

NVIV Price Returns

1-mo N/A
3-mo N/A
6-mo -55.62%
1-year -74.80%
3-year -98.21%
5-year -99.94%
YTD -56.16%
2023 -68.94%
2022 -79.39%
2021 -43.69%
2020 -87.99%
2019 -85.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!